China Medical System (HKG:0867) secured National Medical Products Administration of China's approval for its new drug application for ruxolitinib phosphate cream as treatment for vitiligo, a Wednesday filing with the Hong Kong bourse said.
Vitiligo is a chronic autoimmune disease that causes depigmentation of the skin.
The pharmaceutical innovation and commercialization company's shares fell over 4% on Wednesday's close.
Price (HKD): $7.98, Change: $-0.36, Percent Change: -4.32%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。